BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Welzel TM, McGlynn KA, Hsing AW, O'Brien TR, Pfeiffer RM. Impact of classification of hilar cholangiocarcinomas (Klatskin tumors) on the incidence of intra- and extrahepatic cholangiocarcinoma in the United States. J Natl Cancer Inst. 2006;98:873-875. [PMID: 16788161 DOI: 10.1093/jnci/djj234] [Cited by in Crossref: 243] [Cited by in F6Publishing: 218] [Article Influence: 15.2] [Reference Citation Analysis]
Number Citing Articles
1 Blechacz B, Gores GJ. Tumor-specific marker genes for intrahepatic cholangiocarcinoma: utility and mechanistic insight. J Hepatol 2008;49:160-2. [PMID: 18538440 DOI: 10.1016/j.jhep.2008.05.001] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 0.9] [Reference Citation Analysis]
2 Cardinale V, Semeraro R, Torrice A, Gatto M, Napoli C, Bragazzi MC, Gentile R, Alvaro D. Intra-hepatic and extra-hepatic cholangiocarcinoma: New insight into epidemiology and risk factors. World J Gastrointest Oncol 2010; 2(11): 407-416 [PMID: 21160904 DOI: 10.4251/wjgo.v2.i11.407] [Cited by in CrossRef: 114] [Cited by in F6Publishing: 152] [Article Influence: 9.5] [Reference Citation Analysis]
3 Peng S, Zhang Y, Peng H, Ke Z, Xu L, Su T, Tsung A, Tohme S, Huang H, Zhang Q, Lencioni R, Zeng Z, Peng B, Chen M, Kuang M. Intracellular autocrine VEGF signaling promotes EBDC cell proliferation, which can be inhibited by Apatinib. Cancer Lett. 2016;373:193-202. [PMID: 26805764 DOI: 10.1016/j.canlet.2016.01.015] [Cited by in Crossref: 37] [Cited by in F6Publishing: 40] [Article Influence: 6.2] [Reference Citation Analysis]
4 Shinohara ET, Mitra N, Guo M, Metz JM. Radiation Therapy Is Associated With Improved Survival in the Adjuvant and Definitive Treatment of Intrahepatic Cholangiocarcinoma. International Journal of Radiation Oncology*Biology*Physics 2008;72:1495-501. [DOI: 10.1016/j.ijrobp.2008.03.018] [Cited by in Crossref: 110] [Cited by in F6Publishing: 97] [Article Influence: 7.9] [Reference Citation Analysis]
5 Cardinale V, Bragazzi MC, Carpino G, Torrice A, Fraveto A, Gentile R, Pasqualino V, Melandro F, Aliberti C, Bastianelli C, Brunelli R, Berloco PB, Gaudio E, Alvaro D. Cholangiocarcinoma: increasing burden of classifications. Hepatobiliary Surg Nutr. 2013;2:272-280. [PMID: 24570958 DOI: 10.3978/j.issn.2304-3881.2013.10.02] [Cited by in F6Publishing: 30] [Reference Citation Analysis]
6 Komaya K, Ebata T, Shirai K, Ohira S, Morofuji N, Akutagawa A, Yamaguchi R, Nagino M; Nagoya Surgical Oncology Group. Recurrence after resection with curative intent for distal cholangiocarcinoma. Br J Surg. 2017;104:426-433. [PMID: 28138968 DOI: 10.1002/bjs.10452] [Cited by in Crossref: 45] [Cited by in F6Publishing: 41] [Article Influence: 9.0] [Reference Citation Analysis]
7 Al Mahjoub A, Bouvier V, Menahem B, Bazille C, Fohlen A, Alves A, Mulliri A, Launoy G, Lubrano J. Epidemiology of intrahepatic, perihilar, and distal cholangiocarcinoma in the French population. European Journal of Gastroenterology & Hepatology 2019;31:678-84. [DOI: 10.1097/meg.0000000000001337] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 1.7] [Reference Citation Analysis]
8 Palmer WC, Patel T. Are common factors involved in the pathogenesis of primary liver cancers? A meta-analysis of risk factors for intrahepatic cholangiocarcinoma. J Hepatol 2012;57:69-76. [PMID: 22420979 DOI: 10.1016/j.jhep.2012.02.022] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
9 Wang J, Wang X, Xie S, Yan Z, Li Z, Li Y, Wang L, Jiao F. p53 Status and Its Prognostic Role in Extrahepatic Bile Duct Cancer: A Meta-Analysis of Published Studies. Dig Dis Sci 2011;56:655-62. [DOI: 10.1007/s10620-010-1352-9] [Cited by in Crossref: 15] [Cited by in F6Publishing: 12] [Article Influence: 1.3] [Reference Citation Analysis]
10 Cholangiocarcinoma Working Group. Italian Clinical Practice Guidelines on Cholangiocarcinoma - Part I: Classification, diagnosis and staging. Dig Liver Dis 2020;52:1282-93. [PMID: 32893173 DOI: 10.1016/j.dld.2020.06.045] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
11 Shen Z, Xiao J, Wang J, Lu L, Wan X, Cai X. Peritumoral ductular reaction can be a prognostic factor for intrahepatic cholangiocarcinoma. BMC Gastroenterol 2020;20:322. [PMID: 33008300 DOI: 10.1186/s12876-020-01471-0] [Reference Citation Analysis]
12 Hu MH, Chen LJ, Chen YL, Tsai MS, Shiau CW, Chao TI, Liu CY, Kao JH, Chen KF. Targeting SHP-1-STAT3 signaling: A promising therapeutic approach for the treatment of cholangiocarcinoma. Oncotarget 2017;8:65077-89. [PMID: 29029413 DOI: 10.18632/oncotarget.17779] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 2.2] [Reference Citation Analysis]
13 Patel T. Cholangiocarcinoma--controversies and challenges. Nat Rev Gastroenterol Hepatol. 2011;8:189-200. [PMID: 21460876 DOI: 10.1038/nrgastro.2011.20] [Cited by in Crossref: 204] [Cited by in F6Publishing: 242] [Article Influence: 18.5] [Reference Citation Analysis]
14 Antwi SO, Mousa OY, Patel T. Racial, Ethnic, and Age Disparities in Incidence and Survival of Intrahepatic Cholangiocarcinoma in the United States; 1995-2014. Ann Hepatol. 2018;17:604-614. [PMID: 29893702 DOI: 10.5604/01.3001.0012.0929] [Cited by in Crossref: 20] [Cited by in F6Publishing: 21] [Article Influence: 6.7] [Reference Citation Analysis]
15 Ye XH, Huai JP, Ding J, Chen YP, Sun XC. Smoking, alcohol consumption, and the risk of extrahepatic cholangiocarcinoma: A meta-analysis. World J Gastroenterol 2013; 19(46): 8780-8788 [PMID: 24379600 DOI: 10.3748/wjg.v19.i46.8780] [Cited by in CrossRef: 18] [Cited by in F6Publishing: 16] [Article Influence: 2.0] [Reference Citation Analysis]
16 Meng ZW, Pan W, Hong HJ, Chen JZ, Chen YL. Macroscopic types of intrahepatic cholangiocarcinoma and the eighth edition of AJCC/UICC TNM staging system. Oncotarget. 2017;8:101165-101174. [PMID: 29254154 DOI: 10.18632/oncotarget.20932] [Cited by in Crossref: 21] [Cited by in F6Publishing: 19] [Article Influence: 4.2] [Reference Citation Analysis]
17 Mizrahi JD, Shroff RT. New Treatment Options for Advanced Biliary Tract Cancer. Curr Treat Options in Oncol 2020;21. [DOI: 10.1007/s11864-020-00767-3] [Cited by in Crossref: 18] [Cited by in F6Publishing: 15] [Article Influence: 9.0] [Reference Citation Analysis]
18 Palmer WC, Patel T. Are common factors involved in the pathogenesis of primary liver cancers? J Hepatol. 2012;57:69-76. [PMID: 22420979 DOI: 10.1016/j.jhep.2012.02.022] [Cited by in Crossref: 276] [Cited by in F6Publishing: 302] [Article Influence: 27.6] [Reference Citation Analysis]
19 Meng ZW, Pan W, Hong HJ, Chen JZ, Chen YL. Modified staging classification for intrahepatic cholangiocarcinoma based on the sixth and seventh editions of the AJCC/UICC TNM staging systems. Medicine (Baltimore) 2017;96:e7891. [PMID: 28834905 DOI: 10.1097/MD.0000000000007891] [Cited by in Crossref: 11] [Cited by in F6Publishing: 8] [Article Influence: 2.2] [Reference Citation Analysis]
20 Kaufmann R, Hascher A, Mussbach F, Henklein P, Katenkamp K, Westermann M, Settmacher U. Proteinase-activated receptor 2 (PAR(2)) in cholangiocarcinoma (CCA) cells: effects on signaling and cellular level. Histochem Cell Biol 2012;138:913-24. [PMID: 22892662 DOI: 10.1007/s00418-012-1006-4] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.5] [Reference Citation Analysis]
21 Peng T, Deng X, Tian F, Li Z, Jiang P, Zhao X, Chen G, Chen Y, Zheng P, Li D, Wang S. The interaction of LOXL2 with GATA6 induces VEGFA expression and angiogenesis in cholangiocarcinoma. Int J Oncol 2019;55:657-70. [PMID: 31322171 DOI: 10.3892/ijo.2019.4837] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
22 Boothe D, Hopkins Z, Frandsen J, Lloyd S. Comparison of external beam radiation and brachytherapy to external beam radiation alone for unresectable extrahepatic cholangiocarcinoma. J Gastrointest Oncol 2016;7:580-7. [PMID: 27563448 DOI: 10.21037/jgo.2016.03.14] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.7] [Reference Citation Analysis]
23 Pollom EL, Alagappan M, Park LS, Whittemore AS, Koong AC, Chang DT. Does radiotherapy still have a role in unresected biliary tract cancer? Cancer Med. 2017;6:129-141. [PMID: 27891822 DOI: 10.1002/cam4.975] [Cited by in Crossref: 19] [Cited by in F6Publishing: 14] [Article Influence: 3.2] [Reference Citation Analysis]
24 Spolverato G, Yakoob MY, Kim Y, Alexandrescu S, Marques HP, Lamelas J, Aldrighetti L, Gamblin TC, Maithel SK, Pulitano C, Bauer TW, Shen F, Poultsides GA, Marsh JW, Pawlik TM. Impact of complications on long-term survival after resection of intrahepatic cholangiocarcinoma. Cancer 2015;121:2730-9. [PMID: 25903409 DOI: 10.1002/cncr.29419] [Cited by in Crossref: 45] [Cited by in F6Publishing: 45] [Article Influence: 6.4] [Reference Citation Analysis]
25 Elfaki DH, Gossard AA, Lindor KD. Cholangiocarcinoma: Expanding the Spectrum of Risk Factors. J Gastrointest Canc 2008;39:114-7. [DOI: 10.1007/s12029-008-9040-0] [Cited by in Crossref: 6] [Cited by in F6Publishing: 8] [Article Influence: 0.5] [Reference Citation Analysis]
26 Webb K, Saunders M. Endoscopic management of malignant bile duct strictures. Gastrointest Endosc Clin N Am. 2013;23:313-331. [PMID: 23540963 DOI: 10.1016/j.giec.2012.12.009] [Cited by in Crossref: 19] [Cited by in F6Publishing: 12] [Article Influence: 2.1] [Reference Citation Analysis]
27 Plentz RR, Malek NP. Clinical presentation, risk factors and staging systems of cholangiocarcinoma. Best Pract Res Clin Gastroenterol. 2015;29:245-252. [PMID: 25966425 DOI: 10.1016/j.bpg.2015.02.001] [Cited by in Crossref: 41] [Cited by in F6Publishing: 84] [Article Influence: 5.9] [Reference Citation Analysis]
28 Liu SL, Song ZF, Hu QG, Shan D, Hu SB, Li J, Zheng QC. Serum carbohydrate antigen (CA) 19-9 as a prognostic factor in cholangiocarcinoma: a meta-analysis. Front Med China. 2010;4:457-462. [PMID: 21191748 DOI: 10.1007/s11684-010-0240-1] [Cited by in Crossref: 19] [Cited by in F6Publishing: 14] [Article Influence: 1.6] [Reference Citation Analysis]
29 Hahnvajanawong C, Wattanawongdon W, Chomvarin C, Anantachoke N, Kanthawong S, Sripa B, Reutrakul V. Synergistic effects of isomorellin and forbesione with doxorubicin on apoptosis induction in human cholangiocarcinoma cell lines. Cancer Cell Int 2014;14:68. [PMID: 25866479 DOI: 10.1186/1475-2867-14-68] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 1.1] [Reference Citation Analysis]
30 Abdel-Rahman O, Elsayed Z, Elhalawani H. Gemcitabine-based chemotherapy for advanced biliary tract carcinomas. Cochrane Database Syst Rev. 2018;4:CD011746. [PMID: 29624208 DOI: 10.1002/14651858.cd011746.pub2] [Cited by in Crossref: 9] [Cited by in F6Publishing: 18] [Article Influence: 2.3] [Reference Citation Analysis]
31 Tyson GL, El-Serag HB. Risk factors for cholangiocarcinoma. Hepatology. 2011;54:173-184. [PMID: 21488076 DOI: 10.1002/hep.24351] [Cited by in Crossref: 488] [Cited by in F6Publishing: 443] [Article Influence: 44.4] [Reference Citation Analysis]
32 Kang JS, Higuchi R, He J, Yamamoto M, Wolfgang CL, Cameron JL, Han Y, Son D, Lee S, Choi YJ, Byun Y, Kim H, Kwon W, Kim SW, Park T, Jang JY. Proposal of the minimal number of retrieved regional lymph nodes for accurate staging of distal bile duct cancer and clinical validation of the three-tier lymph node staging system (AJCC 8th edition). J Hepatobiliary Pancreat Sci 2020;27:75-83. [PMID: 31633308 DOI: 10.1002/jhbp.690] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
33 Smoot RL, Blechacz BR, Werneburg NW, Bronk SF, Sinicrope FA, Sirica AE, Gores GJ. A Bax-mediated mechanism for obatoclax-induced apoptosis of cholangiocarcinoma cells. Cancer Res 2010;70:1960-9. [PMID: 20160031 DOI: 10.1158/0008-5472.CAN-09-3535] [Cited by in Crossref: 39] [Cited by in F6Publishing: 22] [Article Influence: 3.3] [Reference Citation Analysis]
34 von Hahn T, Ciesek S, Wegener G, Plentz RR, Weismüller TJ, Wedemeyer H, Manns MP, Greten TF, Malek NP. Epidemiological trends in incidence and mortality of hepatobiliary cancers in Germany. Scandinavian Journal of Gastroenterology 2011;46:1092-8. [DOI: 10.3109/00365521.2011.589472] [Cited by in Crossref: 72] [Cited by in F6Publishing: 71] [Article Influence: 6.5] [Reference Citation Analysis]
35 Singal AG, Rakoski MO, Salgia R, Pelletier S, Welling TH, Fontana RJ, Lok AS, Marrero JA. The clinical presentation and prognostic factors for intrahepatic and extrahepatic cholangiocarcinoma in a tertiary care centre. Aliment Pharmacol Ther. 2010;31:625-633. [PMID: 20003093 DOI: 10.1111/j.1365-2036.2009.04218.x] [Cited by in Crossref: 19] [Cited by in F6Publishing: 63] [Article Influence: 1.5] [Reference Citation Analysis]
36 Parodi A, Fisher D, Giovannini M, Baron T, Conio M. Endoscopic management of hilar cholangiocarcinoma. Nat Rev Gastroenterol Hepatol 2012;9:105-12. [DOI: 10.1038/nrgastro.2011.271] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 1.3] [Reference Citation Analysis]
37 Ebata T, Kosuge T, Hirano S, Unno M, Yamamoto M, Miyazaki M, Kokudo N, Miyagawa S, Takada T, Nagino M. Proposal to modify the International Union Against Cancer staging system for perihilar cholangiocarcinomas. Br J Surg. 2014;101:79-88. [PMID: 24375300 DOI: 10.1002/bjs.9379] [Cited by in Crossref: 84] [Cited by in F6Publishing: 122] [Article Influence: 10.5] [Reference Citation Analysis]
38 Bagante F, Spolverato G, Weiss M, Alexandrescu S, Marques HP, Aldrighetti L, Maithel SK, Pulitano C, Bauer TW, Shen F, Poultsides GA, Soubrane O, Martel G, Groot Koerkamp B, Guglielmi A, Itaru E, Pawlik TM. Defining Long-Term Survivors Following Resection of Intrahepatic Cholangiocarcinoma. J Gastrointest Surg 2017;21:1888-97. [DOI: 10.1007/s11605-017-3550-7] [Cited by in Crossref: 18] [Cited by in F6Publishing: 18] [Article Influence: 3.6] [Reference Citation Analysis]
39 Safarpour AR, Askari H, Ejtehadi F, Azarnezhad A, Raeis-Abdollahi E, Tajbakhsh A, Abazari MF, Tarkesh F, Shamsaeefar A, Niknam R, Sivandzadeh GR, Lankarani KB, Ejtehadi F. Cholangiocarcinoma and liver transplantation: What we know so far? World J Gastrointest Pathophysiol 2021; 12(5): 84-105 [PMID: 34676129 DOI: 10.4291/wjgp.v12.i5.84] [Reference Citation Analysis]
40 Lee H, Ross JS. The potential role of comprehensive genomic profiling to guide targeted therapy for patients with biliary cancer. Therap Adv Gastroenterol. 2017;10:507-520. [PMID: 28567120 DOI: 10.1177/1756283x17698090] [Cited by in Crossref: 29] [Cited by in F6Publishing: 17] [Article Influence: 5.8] [Reference Citation Analysis]
41 Castellano-Megías VM, Ibarrola-de Andrés C, Colina-Ruizdelgado F. Pathological aspects of so called "hilar cholangiocarcinoma". World J Gastrointest Oncol 2013; 5(7): 159-170 [PMID: 23919110 DOI: 10.4251/wjgo.v5.i7.159] [Cited by in CrossRef: 18] [Cited by in F6Publishing: 15] [Article Influence: 2.0] [Reference Citation Analysis]
42 Nathan H, Pawlik TM, Wolfgang CL, Choti MA, Cameron JL, Schulick RD. Trends in survival after surgery for cholangiocarcinoma: a 30-year population-based SEER database analysis. J Gastrointest Surg. 2007;11:1488-1496; discussion 1496-1497. [PMID: 17805937 DOI: 10.1007/s11605-007-0282-0] [Cited by in Crossref: 148] [Cited by in F6Publishing: 195] [Article Influence: 9.9] [Reference Citation Analysis]
43 Rustagi T, Dasanu CA. Risk factors for gallbladder cancer and cholangiocarcinoma: similarities, differences and updates. J Gastrointest Cancer 2012;43:137-47. [PMID: 21597894 DOI: 10.1007/s12029-011-9284-y] [Cited by in Crossref: 42] [Cited by in F6Publishing: 30] [Article Influence: 4.2] [Reference Citation Analysis]
44 Gatto M, Alvaro D. New insights on cholangiocarcinoma. World J Gastrointest Oncol 2010; 2(3): 136-145 [PMID: 21160821 DOI: 10.4251/wjgo.v2.i3.136] [Cited by in CrossRef: 42] [Cited by in F6Publishing: 37] [Article Influence: 3.5] [Reference Citation Analysis]
45 Williams TM, Majithia L, Wang SJ, Thomas CR. Defining the Role of Adjuvant Therapy: Cholangiocarcinoma and Gall Bladder Cancer. Seminars in Radiation Oncology 2014;24:94-104. [DOI: 10.1016/j.semradonc.2014.01.001] [Cited by in Crossref: 21] [Cited by in F6Publishing: 22] [Article Influence: 2.6] [Reference Citation Analysis]
46 Alvaro D, Crocetti E, Ferretti S, Bragazzi MC, Capocaccia R; AISF Cholangiocarcinoma committee. Descriptive epidemiology of cholangiocarcinoma in Italy. Dig Liver Dis. 2010;42:490-495. [PMID: 20022823 DOI: 10.1016/j.dld.2009.10.009] [Cited by in Crossref: 52] [Cited by in F6Publishing: 59] [Article Influence: 4.0] [Reference Citation Analysis]
47 Cercek A, Boerner T, Tan BR, Chou JF, Gönen M, Boucher TM, Hauser HF, Do RKG, Lowery MA, Harding JJ, Varghese AM, Reidy-Lagunes D, Saltz L, Schultz N, Kingham TP, D'Angelica MI, DeMatteo RP, Drebin JA, Allen PJ, Balachandran VP, Lim KH, Sanchez-Vega F, Vachharajani N, Majella Doyle MB, Fields RC, Hawkins WG, Strasberg SM, Chapman WC, Diaz LA Jr, Kemeny NE, Jarnagin WR. Assessment of Hepatic Arterial Infusion of Floxuridine in Combination With Systemic Gemcitabine and Oxaliplatin in Patients With Unresectable Intrahepatic Cholangiocarcinoma: A Phase 2 Clinical Trial. JAMA Oncol 2020;6:60-7. [PMID: 31670750 DOI: 10.1001/jamaoncol.2019.3718] [Cited by in Crossref: 28] [Cited by in F6Publishing: 28] [Article Influence: 14.0] [Reference Citation Analysis]
48 Ma J, Weng L, Wang Z, Jia Y, Liu B, Wu S, Cao Y, Sun X, Yin X, Shang M, Mao A. MiR-124 induces autophagy-related cell death in cholangiocarcinoma cells through direct targeting of the EZH2-STAT3 signaling axis. Exp Cell Res. 2018;366:103-113. [PMID: 29530475 DOI: 10.1016/j.yexcr.2018.02.037] [Cited by in Crossref: 20] [Cited by in F6Publishing: 22] [Article Influence: 5.0] [Reference Citation Analysis]
49 Blechacz B, Komuta M, Roskams T, Gores GJ. Clinical diagnosis and staging of cholangiocarcinoma. Nat Rev Gastroenterol Hepatol. 2011;8:512-522. [PMID: 21808282 DOI: 10.1038/nrgastro.2011.131.] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
50 Ladep NG, Khan SA, Crossey MM, Thillainayagam AV, Taylor-Robinson SD, Toledano MB. Incidence and mortality of primary liver cancer in England and Wales: Changing patterns and ethnic variations. World J Gastroenterol 2014; 20(6): 1544-1553 [PMID: 24587630 DOI: 10.3748/wjg.v20.i6.1544] [Cited by in CrossRef: 26] [Cited by in F6Publishing: 24] [Article Influence: 3.3] [Reference Citation Analysis]
51 Lee BS, Cha BH, Park EC, Roh J. Risk factors for perihilar cholangiocarcinoma: a hospital-based case-control study. Liver Int 2015;35:1048-53. [PMID: 24923595 DOI: 10.1111/liv.12618] [Cited by in Crossref: 19] [Cited by in F6Publishing: 13] [Article Influence: 2.4] [Reference Citation Analysis]
52 Parsi MA. Obesity and cholangiocarcinoma. World J Gastroenterol 2013; 19(4): 457-462 [PMID: 23382624 DOI: 10.3748/wjg.v19.i4.457] [Cited by in CrossRef: 12] [Cited by in F6Publishing: 10] [Article Influence: 1.3] [Reference Citation Analysis]
53 Soares KC, Kamel I, Cosgrove DP, Herman JM, Pawlik TM. Hilar cholangiocarcinoma: diagnosis, treatment options, and management. Hepatobiliary Surg Nutr. 2014;3:18-34. [PMID: 24696835 DOI: 10.3978/j.issn.2304-3881.2014.02.05] [Cited by in F6Publishing: 46] [Reference Citation Analysis]
54 Rizvi S, Gores GJ. Current diagnostic and management options in perihilar cholangiocarcinoma. Digestion 2014;89:216-24. [PMID: 24860985 DOI: 10.1159/000360791] [Cited by in Crossref: 15] [Cited by in F6Publishing: 12] [Article Influence: 1.9] [Reference Citation Analysis]
55 Castro FA, Koshiol J, Hsing AW, Devesa SS. Biliary tract cancer incidence in the United States-Demographic and temporal variations by anatomic site. Int J Cancer 2013;133:1664-71. [PMID: 23504585 DOI: 10.1002/ijc.28161] [Cited by in Crossref: 50] [Cited by in F6Publishing: 46] [Article Influence: 5.6] [Reference Citation Analysis]
56 Yuan C, Hu Z, Wang K, Zou S. Development and Validation a Nomogram for Predicting Overall Survival in Patients With Intrahepatic Cholangiocarcinoma. Front Surg 2021;8:659422. [PMID: 34079814 DOI: 10.3389/fsurg.2021.659422] [Reference Citation Analysis]
57 Adam SZ, Parthasarathy S, Miller FH. Intrahepatic cholangiocarcinomas mimicking other lesions. Abdom Imaging 2015;40:2345-54. [DOI: 10.1007/s00261-015-0480-2] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 1.1] [Reference Citation Analysis]
58 Bridgewater J, Galle PR, Khan SA, Llovet JM, Park JW, Patel T, Pawlik TM, Gores GJ. Guidelines for the diagnosis and management of intrahepatic cholangiocarcinoma. J Hepatol. 2014;60:1268-1289. [PMID: 24681130 DOI: 10.1016/j.jhep.2014.01.021] [Cited by in Crossref: 618] [Cited by in F6Publishing: 635] [Article Influence: 77.3] [Reference Citation Analysis]
59 Lee SY, Kim HS, Choi YJ, Park KH, Shin SW, Kim YH, Tae Kim S. A Prognostic Index to Identify Patients With Intrahepatic Cholangiocarcinoma Who Could Benefit From Gemcitabine Plus Cisplatin. Am J Ther 2016;23:e1449-55. [PMID: 25285672 DOI: 10.1097/MJT.0000000000000112] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 0.6] [Reference Citation Analysis]
60 Khan SA, Tavolari S, Brandi G. Cholangiocarcinoma: Epidemiology and risk factors. Liver Int. 2019;39 Suppl 1:19-31. [PMID: 30851228 DOI: 10.1111/liv.14095] [Cited by in Crossref: 104] [Cited by in F6Publishing: 105] [Article Influence: 34.7] [Reference Citation Analysis]
61 Gnanapandithan K, Allaparthi S, Ukena T, Anand C. Cholangiocarcinoma: another masquerader in the making? J Gastrointest Cancer 2014;45 Suppl 1:14-7. [PMID: 23824629 DOI: 10.1007/s12029-013-9518-2] [Reference Citation Analysis]
62 Wang CC, Tseng MH, Wu SW, Yang TW, Chen HY, Sung WW, Su CC, Wang YT, Lin CC, Tsai MC. Cholecystectomy reduces subsequent cholangiocarcinoma risk in choledocholithiasis patients undergoing endoscopic intervention. World J Gastrointest Oncol 2020; 12(12): 1381-1393 [PMID: 33362909 DOI: 10.4251/wjgo.v12.i12.1381] [Reference Citation Analysis]
63 Ebata T, Kamiya J, Nishio H, Nagasaka T, Nimura Y, Nagino M. The concept of perihilar cholangiocarcinoma is valid. Br J Surg. 2009;96:926-934. [PMID: 19591162 DOI: 10.1002/bjs.6655] [Cited by in Crossref: 71] [Cited by in F6Publishing: 64] [Article Influence: 5.5] [Reference Citation Analysis]
64 Peng NF, Li LQ, Qin X, Guo Y, Peng T, Xiao KY, Chen XG, Yang YF, Su ZX, Chen B, Su M, Qi LN. Evaluation of risk factors and clinicopathologic features for intrahepatic cholangiocarcinoma in Southern China: a possible role of hepatitis B virus. Ann Surg Oncol. 2011;18:1258-1266. [PMID: 21207172 DOI: 10.1245/s10434-010-1458-5] [Cited by in Crossref: 51] [Cited by in F6Publishing: 51] [Article Influence: 4.6] [Reference Citation Analysis]
65 Krasinskas AM. Cholangiocarcinoma. Surgical Pathology Clinics 2018;11:403-29. [DOI: 10.1016/j.path.2018.02.005] [Cited by in Crossref: 28] [Cited by in F6Publishing: 31] [Article Influence: 7.0] [Reference Citation Analysis]
66 Maroni L, Pierantonelli I, Banales JM, Benedetti A, Marzioni M. The significance of genetics for cholangiocarcinoma development. Ann Transl Med 2013;1:28. [PMID: 25332972 DOI: 10.3978/j.issn.2305-5839.2012.10.04] [Cited by in F6Publishing: 14] [Reference Citation Analysis]
67 Ewald F, Grabinski N, Grottke A, Windhorst S, Nörz D, Carstensen L, Staufer K, Hofmann BT, Diehl F, David K. Combined targeting of AKT and mTOR using MK-2206 and RAD001 is synergistic in the treatment of cholangiocarcinoma. Int J Cancer. 2013;133:2065-2076. [PMID: 23588885 DOI: 10.1002/ijc.28214] [Cited by in Crossref: 53] [Cited by in F6Publishing: 51] [Article Influence: 5.9] [Reference Citation Analysis]
68 Lee BS, Park EC, Park SW, Nam CM, Roh J. Hepatitis B virus infection, diabetes mellitus, and their synergism for cholangiocarcinoma development: A case-control study in Korea. World J Gastroenterol 2015; 21(2): 502-510 [PMID: 25593465 DOI: 10.3748/wjg.v21.i2.502] [Cited by in CrossRef: 23] [Cited by in F6Publishing: 24] [Article Influence: 3.3] [Reference Citation Analysis]
69 Saha SK, Zhu AX, Fuchs CS, Brooks GA. Forty-Year Trends in Cholangiocarcinoma Incidence in the U.S.: Intrahepatic Disease on the Rise. Oncologist. 2016;21:594-599. [PMID: 27000463 DOI: 10.1634/theoncologist.2015-0446] [Cited by in Crossref: 255] [Cited by in F6Publishing: 247] [Article Influence: 42.5] [Reference Citation Analysis]
70 Fuller CD, Wang SJ, Choi M, Czito BG, Cornell J, Welzel TM, McGlynn KA, Luh JY, Thomas CR Jr. Multimodality therapy for locoregional extrahepatic cholangiocarcinoma: a population-based analysis. Cancer 2009;115:5175-83. [PMID: 19637356 DOI: 10.1002/cncr.24572] [Cited by in Crossref: 33] [Cited by in F6Publishing: 35] [Article Influence: 2.5] [Reference Citation Analysis]
71 Poruk KE, Pawlik TM, Weiss MJ. Perioperative Management of Hilar Cholangiocarcinoma. J Gastrointest Surg 2015;19:1889-99. [PMID: 26022776 DOI: 10.1007/s11605-015-2854-8] [Cited by in Crossref: 40] [Cited by in F6Publishing: 35] [Article Influence: 5.7] [Reference Citation Analysis]
72 Valle JW, Kelley RK, Nervi B, Oh DY, Zhu AX. Biliary tract cancer.Lancet. 2021;397:428-444. [PMID: 33516341 DOI: 10.1016/S0140-6736(21)00153-7] [Cited by in Crossref: 23] [Cited by in F6Publishing: 21] [Article Influence: 23.0] [Reference Citation Analysis]
73 Wutka A, Palagani V, Barat S, Chen X, El Khatib M, Götze J, Belahmer H, Zender S, Bozko P, Malek NP, Plentz RR. Capsaicin treatment attenuates cholangiocarcinoma carcinogenesis. PLoS One 2014;9:e95605. [PMID: 24748170 DOI: 10.1371/journal.pone.0095605] [Cited by in Crossref: 21] [Cited by in F6Publishing: 22] [Article Influence: 2.6] [Reference Citation Analysis]
74 Wang CC, Tsai MC, Sung WW, Yang TW, Chen HY, Wang YT, Su CC, Tseng MH, Lin CC. Risk of cholangiocarcinoma in patients undergoing therapeutic endoscopic retrograde cholangiopancreatography or cholecystectomy: A population based study. World J Gastrointest Oncol 2019; 11(3): 238-249 [PMID: 30918596 DOI: 10.4251/wjgo.v11.i3.238] [Cited by in CrossRef: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.3] [Reference Citation Analysis]
75 Blechacz BR, Gores GJ. Cholangiocarcinoma. Clinics in Liver Disease 2008;12:131-50. [DOI: 10.1016/j.cld.2007.11.003] [Cited by in Crossref: 156] [Cited by in F6Publishing: 147] [Article Influence: 11.1] [Reference Citation Analysis]
76 Nagaoka S, Yamada D, Eguchi H, Yokota Y, Iwagami Y, Asaoka T, Noda T, Kawamoto K, Gotoh K, Kobayashi S, Miyoshi E, Doki Y, Mori M. The blockade of interleukin-33 released by hepatectomy would be a promising treatment option for cholangiocarcinoma. Cancer Sci 2021;112:347-58. [PMID: 33098728 DOI: 10.1111/cas.14709] [Reference Citation Analysis]
77 Currie BM, Soulen MC. Decision Making: Intra-arterial Therapies for Cholangiocarcinoma-TACE and TARE. Semin Intervent Radiol 2017;34:92-100. [PMID: 28579676 DOI: 10.1055/s-0037-1602591] [Cited by in Crossref: 19] [Cited by in F6Publishing: 15] [Article Influence: 3.8] [Reference Citation Analysis]
78 Cardinale V. Classifications and misclassification in cholangiocarcinoma. Liver Int. 2019;39:260-262. [PMID: 30694026 DOI: 10.1111/liv.13998] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
79 Kilander C, Lagergren J, Ljung R, Sadr-azodi O. The population-based incidence and mortality of biliary tract cancer in Sweden. Cancer Epidemiology 2018;56:14-20. [DOI: 10.1016/j.canep.2018.06.004] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
80 Byrling J, Andersson B, Marko-varga G, Andersson R. Cholangiocarcinoma – current classification and challenges towards personalised medicine. Scandinavian Journal of Gastroenterology 2016;51:641-3. [DOI: 10.3109/00365521.2015.1127409] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
81 Andrianello S, Paiella S, Allegrini V, Ramera M, Pulvirenti A, Malleo G, Salvia R, Bassi C. Pancreaticoduodenectomy for distal cholangiocarcinoma: surgical results, prognostic factors, and long-term follow-up. Langenbecks Arch Surg 2015;400:623-8. [DOI: 10.1007/s00423-015-1320-0] [Cited by in Crossref: 32] [Cited by in F6Publishing: 29] [Article Influence: 4.6] [Reference Citation Analysis]
82 Florio AA, Ferlay J, Znaor A, Ruggieri D, Alvarez CS, Laversanne M, Bray F, McGlynn KA, Petrick JL. Global trends in intrahepatic and extrahepatic cholangiocarcinoma incidence from 1993 to 2012. Cancer. 2020;126:2666-2678. [PMID: 32129902 DOI: 10.1002/cncr.32803] [Cited by in Crossref: 35] [Cited by in F6Publishing: 31] [Article Influence: 17.5] [Reference Citation Analysis]
83 Pericleous M, Khan SA. Epidemiology of HPB malignancy in the elderly. European Journal of Surgical Oncology 2021;47:503-13. [DOI: 10.1016/j.ejso.2020.03.222] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
84 Selvadurai S, Mann K, Mithra S, Bridgewater J, Malik H, Khan SA. Cholangiocarcinoma miscoding in hepatobiliary centres. Eur J Surg Oncol 2021;47:635-9. [PMID: 33032867 DOI: 10.1016/j.ejso.2020.09.039] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
85 Braunwarth E, Stättner S, Fodor M, Cardini B, Resch T, Oberhuber R, Putzer D, Bale R, Maglione M, Margreiter C, Schneeberger S, Öfner D, Primavesi F. Surgical techniques and strategies for the treatment of primary liver tumours: hepatocellular and cholangiocellular carcinoma. Eur Surg 2018;50:100-12. [PMID: 29875798 DOI: 10.1007/s10353-018-0537-x] [Cited by in Crossref: 9] [Cited by in F6Publishing: 6] [Article Influence: 2.3] [Reference Citation Analysis]
86 da Silva TE, Costa-Silva M, Correa CG, Denardin G, Alencar MLA, Coelho MSPH, Muraro-Wildner L, Luiza-Bazzo M, González-Chica DA, Dantas-Correa EB, Narciso-Schiavon JL, Schiavon LL. Clinical Significance of Serum Adiponectin and Resistin Levels in Liver Cirrhosis. Ann Hepatol 2018;17:286-99. [PMID: 29469045 DOI: 10.5604/01.3001.0010.8659] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 3.0] [Reference Citation Analysis]
87 Beal EW, Tumin D, Moris D, Zhang XF, Chakedis J, Dilhoff M, Schmidt CM, Pawlik TM. Cohort contributions to trends in the incidence and mortality of intrahepatic cholangiocarcinoma. Hepatobiliary Surg Nutr 2018;7:270-6. [PMID: 30221154 DOI: 10.21037/hbsn.2018.03.16] [Cited by in Crossref: 11] [Cited by in F6Publishing: 16] [Article Influence: 2.8] [Reference Citation Analysis]
88 Dickson PV, Behrman SW. Distal Cholangiocarcinoma. Surgical Clinics of North America 2014;94:325-42. [DOI: 10.1016/j.suc.2013.12.004] [Cited by in Crossref: 28] [Cited by in F6Publishing: 20] [Article Influence: 3.5] [Reference Citation Analysis]
89 Khan J, Ullah A, Matolo N, Waheed A, Nama N, Khan T, Tareen B, Khan Z, Singh SG, Cason FD. Klatskin Tumor in the Light of ICD-O-3: A Population-Based Clinical Outcome Study Involving 1,144 Patients from the Surveillance, Epidemiology, and End Result (SEER) Database (2001-2012). Cureus 2021;13:e18941. [PMID: 34815893 DOI: 10.7759/cureus.18941] [Reference Citation Analysis]
90 Shinohara ET, Mitra N, Guo M, Metz JM. Radiotherapy is associated with improved survival in adjuvant and palliative treatment of extrahepatic cholangiocarcinomas. Int J Radiat Oncol Biol Phys. 2009;74:1191-1198. [PMID: 19201549 DOI: 10.1016/j.ijrobp.2008.09.017] [Cited by in Crossref: 54] [Cited by in F6Publishing: 45] [Article Influence: 4.2] [Reference Citation Analysis]
91 Baheti AD, Tirumani SH, Shinagare AB, Rosenthal MH, Hornick JL, Ramaiya NH, Wolpin BM. Correlation of CT patterns of primary intrahepatic cholangiocarcinoma at the time of presentation with the metastatic spread and clinical outcomes: retrospective study of 92 patients. Abdom Imaging. 2014;39:1193-1201. [PMID: 24869789 DOI: 10.1007/s00261-014-0167-0] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 1.7] [Reference Citation Analysis]
92 Mosnier JF, Kandel C, Cazals-Hatem D, Bou-Hanna C, Gournay J, Jarry A, Laboisse CL. N-cadherin serves as diagnostic biomarker in intrahepatic and perihilar cholangiocarcinomas. Mod Pathol. 2009;22:182-190. [PMID: 18622386 DOI: 10.1038/modpathol.2008.123] [Cited by in Crossref: 39] [Cited by in F6Publishing: 79] [Article Influence: 2.8] [Reference Citation Analysis]
93 Hou L, Jiang J, Liu B, Han W, Wu Y, Zou X, Xue F, Chen Y, Zhang B, Pang H, Wang Y, Wang Z, Hu Y, Li J. Is exposure to tobacco associated with extrahepatic cholangiocarcinoma epidemics? A retrospective proportional mortality study in China. BMC Cancer 2019;19:348. [PMID: 30975121 DOI: 10.1186/s12885-019-5484-9] [Reference Citation Analysis]
94 Pinter M, Hucke F, Zielonke N, Waldhör T, Trauner M, Peck-Radosavljevic M, Sieghart W. Incidence and mortality trends for biliary tract cancers in Austria. Liver Int 2014;34:1102-8. [PMID: 24119058 DOI: 10.1111/liv.12325] [Cited by in Crossref: 20] [Cited by in F6Publishing: 21] [Article Influence: 2.2] [Reference Citation Analysis]
95 She WH, Cheung TT, Ma KW, Tsang SHY, Dai WC, Chan ACY, Lo CM. Defining the optimal bilirubin level before hepatectomy for hilar cholangiocarcinoma. BMC Cancer 2020;20:914. [PMID: 32967634 DOI: 10.1186/s12885-020-07385-0] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
96 Cho MS, Kim SH, Park SW, Lim JH, Choi GH, Park JS, Chung JB, Kim KS. Surgical outcomes and predicting factors of curative resection in patients with hilar cholangiocarcinoma: 10-year single-institution experience. J Gastrointest Surg 2012;16:1672-9. [PMID: 22798185 DOI: 10.1007/s11605-012-1960-0] [Cited by in Crossref: 55] [Cited by in F6Publishing: 50] [Article Influence: 5.5] [Reference Citation Analysis]
97 Kang MJ, Lim J, Han SS, Park HM, Kim SW, Won YJ, Park SJ. Impact of changes in the topographic classification of Klatskin tumor on incidence of intra- and extrahepatic bile duct cancer: A population-based national cancer registry study. J Hepatobiliary Pancreat Sci 2021. [PMID: 33615747 DOI: 10.1002/jhbp.916] [Reference Citation Analysis]
98 Bluethner T, Niederhagen M, Caca K, Serr F, Witzigmann H, Moebius C, Mossner J, Wiedmann M. Inhibition of histone deacetylase for the treatment of biliary tract cancer: A new effective pharmacological approach. World J Gastroenterol 2007; 13(35): 4761-4770 [PMID: 17729398 DOI: 10.3748/wjg.v13.i35.4761] [Cited by in CrossRef: 16] [Cited by in F6Publishing: 16] [Article Influence: 1.1] [Reference Citation Analysis]
99 Yang Z. The utility of villin and mammaglobin in the differential diagnosis between intrahepatic cholangiocarcinoma and breast cancer. Appl Immunohistochem Mol Morphol 2015;23:19-25. [PMID: 25153498 DOI: 10.1097/PAI.0000000000000035] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.4] [Reference Citation Analysis]
100 Blechacz B, Gores GJ. Cholangiocarcinoma: advances in pathogenesis, diagnosis, and treatment. Hepatology 2008;48:308-21. [PMID: 18536057 DOI: 10.1002/hep.22310] [Cited by in Crossref: 470] [Cited by in F6Publishing: 444] [Article Influence: 33.6] [Reference Citation Analysis]
101 Martin Huertas R, Fuentes-Mateos R, Serrano Domingo JJ, Corral de la Fuente E, Rodríguez-Garrote M. Albumin-bound paclitaxel as new treatment for metastatic cholangiocarcinoma: A case report. World J Clin Oncol 2020; 11(10): 844-853 [PMID: 33200077 DOI: 10.5306/wjco.v11.i10.844] [Reference Citation Analysis]
102 Liu F, Zhu C, Gao P, Zheng S, Li C. Ubiquitin-conjugating enzyme E2T regulates cell proliferation and migration in cholangiocarcinoma. Anticancer Drugs 2020;31:836-46. [PMID: 32796405 DOI: 10.1097/CAD.0000000000000955] [Reference Citation Analysis]
103 Yang JD, Kim B, Sanderson SO, Sauver JS, Yawn BP, Larson JJ, Therneau TM, Roberts LR, Gores GJ, Kim WR. Biliary tract cancers in Olmsted County, Minnesota, 1976-2008. Am J Gastroenterol. 2012;107:1256-1262. [PMID: 22751468 DOI: 10.1038/ajg.2012.173] [Cited by in Crossref: 49] [Cited by in F6Publishing: 42] [Article Influence: 4.9] [Reference Citation Analysis]
104 Ariizumi S, Yamamoto M. Intrahepatic cholangiocarcinoma and cholangiolocellular carcinoma in cirrhosis and chronic viral hepatitis. Surg Today 2015;45:682-7. [PMID: 25253466 DOI: 10.1007/s00595-014-1031-0] [Cited by in Crossref: 17] [Cited by in F6Publishing: 16] [Article Influence: 2.1] [Reference Citation Analysis]
105 Azizi S, Kheirandiah R, Sami M. Slaughterhouse report of intrahepatic cholangiocarcinoma in a Holstein cow. Comp Clin Pathol 2016;25:1321-4. [DOI: 10.1007/s00580-016-2324-z] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
106 Blechacz BR, Sanchez W, Gores GJ. A conceptual proposal for staging ductal cholangiocarcinoma. Curr Opin Gastroenterol 2009;25:238-9. [PMID: 19387257 DOI: 10.1097/MOG.0b013e3283292383] [Cited by in Crossref: 30] [Cited by in F6Publishing: 11] [Article Influence: 2.3] [Reference Citation Analysis]
107 Zheng WH, Yu T, Luo YH, Wang Y, Liu YF, Hua XD, Lin J, Ma ZH, Ai FL, Wang TL. Clinical efficacy of gemcitabine and cisplatin-based transcatheter arterial chemoembolization combined with radiotherapy in hilar cholangiocarcinoma. World J Gastrointest Oncol 2019; 11(6): 489-498 [PMID: 31236199 DOI: 10.4251/wjgo.v11.i6.489] [Cited by in CrossRef: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
108 Coelho R, Silva M, Rodrigues-Pinto E, Cardoso H, Lopes S, Pereira P, Vilas-Boas F, Santos-Antunes J, Costa-Maia J, Macedo G. CA 19-9 as a Marker of Survival and a Predictor of Metastization in Cholangiocarcinoma. GE Port J Gastroenterol 2017;24:114-21. [PMID: 28848795 DOI: 10.1159/000452691] [Cited by in Crossref: 11] [Cited by in F6Publishing: 18] [Article Influence: 2.2] [Reference Citation Analysis]
109 Menon S, Mathew R. Association between metabolic syndrome and hepatobiliary cancers: A case-control study. Indian J Gastroenterol 2019;38:61-8. [DOI: 10.1007/s12664-018-0925-y] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 2.3] [Reference Citation Analysis]
110 Samukawa E, Fujihara S, Oura K, Iwama H, Yamana Y, Tadokoro T, Chiyo T, Kobayashi K, Morishita A, Nakahara M, Kobara H, Mori H, Okano K, Suzuki Y, Himoto T, Masaki T. Angiotensin receptor blocker telmisartan inhibits cell proliferation and tumor growth of cholangiocarcinoma through cell cycle arrest. Int J Oncol 2017;51:1674-84. [PMID: 29075786 DOI: 10.3892/ijo.2017.4177] [Cited by in Crossref: 17] [Cited by in F6Publishing: 19] [Article Influence: 3.4] [Reference Citation Analysis]
111 Walter D, Ferstl P, Waidmann O, Trojan J, Hartmann S, Schnitzbauer AA, Zeuzem S, Kraywinkel K. Cholangiocarcinoma in Germany: Epidemiologic trends and impact of misclassification. Liver Int 2019;39:316-23. [PMID: 30176117 DOI: 10.1111/liv.13954] [Cited by in Crossref: 11] [Cited by in F6Publishing: 8] [Article Influence: 2.8] [Reference Citation Analysis]
112 Loeuillard E, Fischbach SR, Gores GJ, Rizvi S. Animal models of cholangiocarcinoma. Biochim Biophys Acta Mol Basis Dis 2019;1865:982-92. [PMID: 29627364 DOI: 10.1016/j.bbadis.2018.03.026] [Cited by in Crossref: 21] [Cited by in F6Publishing: 20] [Article Influence: 5.3] [Reference Citation Analysis]
113 Shin HR, Oh JK, Lim MK, Shin A, Kong HJ, Jung KW, Won YJ, Park S, Park SJ, Hong ST. Descriptive epidemiology of cholangiocarcinoma and clonorchiasis in Korea. J Korean Med Sci. 2010;25:1011-1016. [PMID: 20592891 DOI: 10.3346/jkms.2010.25.7.1011] [Cited by in Crossref: 74] [Cited by in F6Publishing: 60] [Article Influence: 6.2] [Reference Citation Analysis]
114 Hu J, Tang J, Lin C, Chu Y, Liu N. Preoperative staging of cholangiocarcinoma and biliary carcinoma using 18F-fluorodeoxyglucose positron emission tomography: a meta-analysis. J Investig Med 2018;66:52-61. [DOI: 10.1136/jim-2017-000472] [Cited by in Crossref: 20] [Cited by in F6Publishing: 14] [Article Influence: 4.0] [Reference Citation Analysis]
115 Baheti AD, Tirumani SH, Rosenthal MH, Shinagare AB, Ramaiya NH. Diagnosis and management of intrahepatic cholangiocarcinoma: a comprehensive update for the radiologist. Clin Radiol. 2014;69:e463-e470. [PMID: 25240565 DOI: 10.1016/j.crad.2014.08.003] [Cited by in Crossref: 10] [Cited by in F6Publishing: 12] [Article Influence: 1.3] [Reference Citation Analysis]
116 Affo S, Yu LX, Schwabe RF. The Role of Cancer-Associated Fibroblasts and Fibrosis in Liver Cancer. Annu Rev Pathol 2017;12:153-86. [PMID: 27959632 DOI: 10.1146/annurev-pathol-052016-100322] [Cited by in Crossref: 183] [Cited by in F6Publishing: 189] [Article Influence: 30.5] [Reference Citation Analysis]
117 Tsai MS, Lee PH, Lin CL, Peng CL, Kao CH. Type II diabetes mellitus is associated with a reduced risk of cholangiocarcinoma in patients with biliary tract diseases. Int J Cancer 2015;136:2409-17. [PMID: 25348605 DOI: 10.1002/ijc.29292] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.6] [Reference Citation Analysis]
118 Mosadeghi S, Liu B, Bhuket T, Wong RJ. Sex-specific and race/ethnicity-specific disparities in cholangiocarcinoma incidence and prevalence in the USA: An updated analysis of the 2000-2011 Surveillance, Epidemiology and End Results registry. Hepatol Res 2016;46:669-77. [PMID: 26508039 DOI: 10.1111/hepr.12605] [Cited by in Crossref: 26] [Cited by in F6Publishing: 22] [Article Influence: 3.7] [Reference Citation Analysis]
119 Mao K, Jiang W, Liu J, Wang J. Incidence of subsequent cholangiocarcinomas after another malignancy: trends in a population-based study. Medicine (Baltimore) 2015;94:e596. [PMID: 25715268 DOI: 10.1097/MD.0000000000000596] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 0.9] [Reference Citation Analysis]
120 Yang W, Li Y, Song X, Xu J, Xie J. Genome-wide analysis of long noncoding RNA and mRNA co-expression profile in intrahepatic cholangiocarcinoma tissue by RNA sequencing. Oncotarget 2017;8:26591-9. [PMID: 28427159 DOI: 10.18632/oncotarget.15721] [Cited by in Crossref: 16] [Cited by in F6Publishing: 21] [Article Influence: 4.0] [Reference Citation Analysis]
121 Park HS, Park JS, Chun YJ, Roh YH, Moon J, Chon HJ, Choi HJ, Park JS, Lee DK, Lee SJ, Yoon DS, Jeung HC. Prognostic Factors and Scoring Model for Survival in Metastatic Biliary Tract Cancer. Cancer Res Treat 2017;49:1127-39. [PMID: 28161931 DOI: 10.4143/crt.2016.538] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 2.4] [Reference Citation Analysis]
122 Tyson GL, Ilyas JA, Duan Z, Green LK, Younes M, El-Serag HB, Davila JA. Secular trends in the incidence of cholangiocarcinoma in the USA and the impact of misclassification. Dig Dis Sci 2014;59:3103-10. [PMID: 25204668 DOI: 10.1007/s10620-014-3276-2] [Cited by in Crossref: 60] [Cited by in F6Publishing: 61] [Article Influence: 7.5] [Reference Citation Analysis]
123 Romiti A, D’Antonio C, Zullo A, Sarcina I, Di Rocco R, Barucca V, Durante V, Marchetti P. Chemotherapy for the biliary tract cancers: moving toward improved survival time. J Gastrointest Cancer. 2012;43:396-404. [PMID: 22328060 DOI: 10.1007/s12029-012-9369-2] [Cited by in Crossref: 17] [Cited by in F6Publishing: 16] [Article Influence: 1.9] [Reference Citation Analysis]
124 Sandler KA, Veruttipong D, Agopian VG, Finn RS, Hong JC, Kaldas FM, Sadeghi S, Busuttil RW, Lee P. Stereotactic body radiotherapy (SBRT) for locally advanced extrahepatic and intrahepatic cholangiocarcinoma. Adv Radiat Oncol 2016;1:237-43. [PMID: 28740893 DOI: 10.1016/j.adro.2016.10.008] [Cited by in Crossref: 19] [Cited by in F6Publishing: 18] [Article Influence: 3.2] [Reference Citation Analysis]
125 Danese E, Ruzzenente O, Ruzzenente A, Iacono C, Bertuzzo F, Gelati M, Conci S, Bendinelli S, Bonizzato G, Guglielmi A, Salvagno GL, Lippi G, Guidi GC. Assessment of bile and serum mucin5AC in cholangiocarcinoma: diagnostic performance and biologic significance. Surgery 2014;156:1218-24. [PMID: 25151557 DOI: 10.1016/j.surg.2014.05.006] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 1.0] [Reference Citation Analysis]
126 Wu T, Levy M, Correa AM, Rosen CB, Abraham SC. Biliary intraepithelial neoplasia in patients without chronic biliary disease: Analysis of liver explants with alcoholic cirrhosis, hepatitis C infection, and noncirrhotic liver diseases. Cancer 2009;115:4564-75. [DOI: 10.1002/cncr.24471] [Cited by in Crossref: 53] [Cited by in F6Publishing: 44] [Article Influence: 4.1] [Reference Citation Analysis]
127 Gad MM, Saad AM, Faisaluddin M, Gaman MA, Ruhban IA, Jazieh KA, Al-husseini MJ, Simons-linares CR, Sonbol MB, Estfan BN. Epidemiology of Cholangiocarcinoma; United States Incidence and Mortality Trends. Clinics and Research in Hepatology and Gastroenterology 2020;44:885-93. [DOI: 10.1016/j.clinre.2020.03.024] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 5.0] [Reference Citation Analysis]
128 Ghouri YA, Mian I, Blechacz B. Cancer review: Cholangiocarcinoma. J Carcinog. 2015;14:1. [PMID: 25788866 DOI: 10.4103/1477-3163.151940] [Cited by in Crossref: 83] [Cited by in F6Publishing: 83] [Article Influence: 11.9] [Reference Citation Analysis]
129 Azodo IA, Parks RW, Garden OJ. Epidemiology of Cholangiocarcinoma and Gallbladder Carcinoma. In: Herman JM, Pawlik TM, Thomas, CR, editors. Biliary Tract and Gallbladder Cancer. Berlin: Springer Berlin Heidelberg; 2014. pp. 1-31. [DOI: 10.1007/978-3-642-40558-7_1] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
130 Ho J, Curley SA. Diagnosis and Management of Intrahepatic and Extrahepatic Cholangiocarcinoma. Cancer Treat Res 2016;168:121-63. [PMID: 29206368 DOI: 10.1007/978-3-319-34244-3_7] [Cited by in Crossref: 2] [Article Influence: 0.3] [Reference Citation Analysis]
131 Erichsen R, Jepsen P, Vilstrup H, Ekbom A, Sørensen HT. Incidence and prognosis of cholangiocarcinoma in Danish patients with and without inflammatory bowel disease: a national cohort study, 1978-2003. Eur J Epidemiol 2009;24:513-20. [PMID: 19557525 DOI: 10.1007/s10654-009-9365-4] [Cited by in Crossref: 34] [Cited by in F6Publishing: 31] [Article Influence: 2.6] [Reference Citation Analysis]
132 Blechacz B, Komuta M, Roskams T, Gores GJ. Clinical diagnosis and staging of cholangiocarcinoma. Nat Rev Gastroenterol Hepatol. 2011;8:512-522. [PMID: 21808282 DOI: 10.1038/nrgastro.2011.131] [Cited by in Crossref: 348] [Cited by in F6Publishing: 355] [Article Influence: 31.6] [Reference Citation Analysis]
133 Lieke T, Ramackers W, Bergmann S, Klempnauer J, Winkler M, Klose J. Impact of Salinomycin on human cholangiocarcinoma: induction of apoptosis and impairment of tumor cell proliferation in vitro. BMC Cancer 2012;12:466. [PMID: 23057720 DOI: 10.1186/1471-2407-12-466] [Cited by in Crossref: 24] [Cited by in F6Publishing: 26] [Article Influence: 2.4] [Reference Citation Analysis]
134 Augustine MM, Fong Y. Epidemiology and risk factors of biliary tract and primary liver tumors. Surg Oncol Clin N Am. 2014;23:171-188. [PMID: 24560105 DOI: 10.1016/j.soc.2013.10.001] [Cited by in Crossref: 23] [Cited by in F6Publishing: 23] [Article Influence: 2.6] [Reference Citation Analysis]
135 Rumgay H, Ferlay J, de Martel C, Georges D, Ibrahim AS, Zheng R, Wei W, Lemmens VEPP, Soerjomataram I. Global, regional and national burden of primary liver cancer by subtype. Eur J Cancer 2022;161:108-18. [PMID: 34942552 DOI: 10.1016/j.ejca.2021.11.023] [Reference Citation Analysis]
136 Boueroy P, Hahnvajanawong C, Boonmars T, Saensa-Ard S, Anantachoke N, Vaeteewoottacharn K, Reutrakul V. Antitumor effect of forbesione isolated from Garcinia hanburyi on cholangiocarcinoma in vitro and in vivo. Oncol Lett 2016;12:4685-98. [PMID: 28101220 DOI: 10.3892/ol.2016.5284] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
137 Chung CW, Kim CH, Choi KH, Yoo JJ, Kim DH, Chung KD, Jeong YI, Kang DH. Effect of surfactant on 5-aminolevulinic acid uptake and PpIX generation in human cholangiocarcinoma cell. Eur J Pharm Biopharm 2012;80:453-8. [PMID: 22024407 DOI: 10.1016/j.ejpb.2011.10.008] [Cited by in Crossref: 10] [Cited by in F6Publishing: 13] [Article Influence: 0.9] [Reference Citation Analysis]
138 Rizvi S, Gores GJ. Pathogenesis, diagnosis, and management of cholangiocarcinoma. Gastroenterology. 2013;145:1215-1229. [PMID: 24140396 DOI: 10.1053/j.gastro.2013.10.013] [Cited by in Crossref: 622] [Cited by in F6Publishing: 626] [Article Influence: 69.1] [Reference Citation Analysis]
139 Salati M, Filippi R, Vivaldi C, Caputo F, Leone F, Salani F, Cerma K, Aglietta M, Fornaro L, Sperti E, Di Maio M, Ortega C, Fenocchio E, Lombardi P, Cagnazzo C, Depetris I, Gelsomino F, Spallanzani A, Santini D, Silvestris N, Aprile G, Roviello G, Scartozzi M, Cascinu S, Casadei-Gardini A. The prognostic nutritional index predicts survival and response to first-line chemotherapy in advanced biliary cancer. Liver Int 2020;40:704-11. [PMID: 31773848 DOI: 10.1111/liv.14314] [Cited by in Crossref: 18] [Cited by in F6Publishing: 14] [Article Influence: 6.0] [Reference Citation Analysis]
140 Ma K, Dong B, Wang L, Zhao C, Fu Z, Che C, Liu W, Yang Z, Liang R. Nomograms for predicting overall survival and cancer-specific survival in patients with surgically resected intrahepatic cholangiocarcinoma. Cancer Manag Res 2019;11:6907-29. [PMID: 31440084 DOI: 10.2147/CMAR.S212149] [Cited by in Crossref: 3] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
141 Welzel TM, Graubard BI, Zeuzem S, El-Serag HB, Davila JA, McGlynn KA. Metabolic syndrome increases the risk of primary liver cancer in the United States: a study in the SEER-Medicare database. Hepatology. 2011;54:463-471. [PMID: 21538440 DOI: 10.1002/hep.24397] [Cited by in Crossref: 338] [Cited by in F6Publishing: 357] [Article Influence: 30.7] [Reference Citation Analysis]
142 Cardinale V, Carpino G, Reid L, Gaudio E, Alvaro D. Multiple cells of origin in cholangiocarcinoma underlie biological, epidemiological and clinical heterogeneity. World J Gastrointest Oncol 2012; 4(5): 94-102 [PMID: 22645632 DOI: 10.4251/wjgo.v4.i5.94] [Cited by in CrossRef: 73] [Cited by in F6Publishing: 109] [Article Influence: 7.3] [Reference Citation Analysis]
143 Vitale A, Spolverato G, Bagante F, Gani F, Popescu I, Marques HP, Aldrighetti L, Gamblin TC, Maithel SK, Sandroussi C, Bauer TW, Shen F, Poultsides GA, Marsh JW, Pawlik TM. A multi-institutional analysis of elderly patients undergoing a liver resection for intrahepatic cholangiocarcinoma. J Surg Oncol 2016;113:420-6. [PMID: 27100027 DOI: 10.1002/jso.24148] [Cited by in Crossref: 24] [Cited by in F6Publishing: 20] [Article Influence: 4.0] [Reference Citation Analysis]
144 Gavriilidis P, Askari A, Roberts KJ, Sutcliffe RP. Appraisal of the current guidelines for management of cholangiocarcinoma-using the Appraisal of Guidelines Research and Evaluation II (AGREE II) Instrument. Hepatobiliary Surg Nutr 2020;9:126-35. [PMID: 32355672 DOI: 10.21037/hbsn.2019.09.06] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 2.5] [Reference Citation Analysis]
145 Bertuccio P, Malvezzi M, Carioli G, Hashim D, Boffetta P, El-Serag HB, La Vecchia C, Negri E. Global trends in mortality from intrahepatic and extrahepatic cholangiocarcinoma. J Hepatol. 2019;71:104-114. [PMID: 30910538 DOI: 10.1016/j.jhep.2019.03.013] [Cited by in Crossref: 77] [Cited by in F6Publishing: 87] [Article Influence: 25.7] [Reference Citation Analysis]
146 Sungkasubun P, Siripongsakun S, Akkarachinorate K, Vidhyarkorn S, Worakitsitisatorn A, Sricharunrat T, Singharuksa S, Chanwat R, Bunchaliew C, Charoenphattharaphesat S, Molek R, Yimyaem M, Sornsamdang G, Soonklang K, Wittayasak K, Auewarakul CU, Mahidol C. Ultrasound screening for cholangiocarcinoma could detect premalignant lesions and early-stage diseases with survival benefits: a population-based prospective study of 4,225 subjects in an endemic area. BMC Cancer 2016;16:346. [PMID: 27251649 DOI: 10.1186/s12885-016-2390-2] [Cited by in Crossref: 17] [Cited by in F6Publishing: 16] [Article Influence: 2.8] [Reference Citation Analysis]
147 Kato A, Shimizu H, Ohtsuka M, Yoshidome H, Yoshitomi H, Furukawa K, Takeuchi D, Takayashiki T, Kimura F, Miyazaki M. Surgical resection after downsizing chemotherapy for initially unresectable locally advanced biliary tract cancer: a retrospective single-center study. Ann Surg Oncol. 2013;20:318-324. [PMID: 23149849 DOI: 10.1245/s10434-012-2312-8] [Cited by in Crossref: 75] [Cited by in F6Publishing: 64] [Article Influence: 7.5] [Reference Citation Analysis]
148 Longerich T, Breuhahn K, Schirmacher P. Molecular Pathology of Liver Tumors. In: Cheng L, Eble JN, editors. Molecular Surgical Pathology. New York: Springer; 2013. pp. 43-63. [DOI: 10.1007/978-1-4614-4900-3_3] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
149 Khan SA, Toledano MB, Taylor-Robinson SD. Epidemiology, risk factors, and pathogenesis of cholangiocarcinoma. HPB (Oxford). 2008;10:77-82. [PMID: 18773060 DOI: 10.1080/13651820801992641] [Cited by in Crossref: 283] [Cited by in F6Publishing: 251] [Article Influence: 23.6] [Reference Citation Analysis]
150 Yao Y, Jiao D, Liu Z, Chen J, Zhou X, Li Z, Li J, Han X. Novel miRNA Predicts Survival and Prognosis of Cholangiocarcinoma Based on RNA-seq Data and In Vitro Experiments. Biomed Res Int 2020;2020:5976127. [PMID: 33490245 DOI: 10.1155/2020/5976127] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
151 Zender L, Malek NP. [Diagnostics and treatment of cholangiocellular carcinoma]. Internist (Berl) 2016;57:1191-205. [PMID: 27822622 DOI: 10.1007/s00108-016-0128-5] [Reference Citation Analysis]
152 Welzel TM, Mellemkjaer L, Gloria G, Sakoda LC, Hsing AW, El Ghormli L, Olsen JH, McGlynn KA. Risk factors for intrahepatic cholangiocarcinoma in a low-risk population: a nationwide case-control study. Int J Cancer. 2007;120:638-641. [PMID: 17109384 DOI: 10.1002/ijc.22283] [Cited by in Crossref: 122] [Cited by in F6Publishing: 106] [Article Influence: 8.1] [Reference Citation Analysis]
153 Valero V 3rd, Cosgrove D, Herman JM, Pawlik TM. Management of perihilar cholangiocarcinoma in the era of multimodal therapy. Expert Rev Gastroenterol Hepatol 2012;6:481-95. [PMID: 22928900 DOI: 10.1586/egh.12.20] [Cited by in Crossref: 36] [Cited by in F6Publishing: 33] [Article Influence: 4.0] [Reference Citation Analysis]
154 Moazzami B, Majidzadeh-A K, Dooghaie-Moghadam A, Eslami P, Razavi-Khorasani N, Iravani S, Khoshdel A, Shahi F, Dashti H, Mehrvar A, Nassiri Toosi M. Cholangiocarcinoma: State of the Art. J Gastrointest Cancer 2020;51:774-81. [PMID: 32157571 DOI: 10.1007/s12029-020-00390-3] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 6.0] [Reference Citation Analysis]
155 Bergquist A, von Seth E. Epidemiology of cholangiocarcinoma. Best Pract Res Clin Gastroenterol. 2015;29:221-232. [PMID: 25966423 DOI: 10.1016/j.bpg.2015.02.003] [Cited by in Crossref: 190] [Cited by in F6Publishing: 169] [Article Influence: 27.1] [Reference Citation Analysis]
156 Xu JY, Ye ZL, Jiang DQ, He JC, Ding YM, Li LF, Lv SQ, Wang Y, Jin HJ, Qian QJ. Mesothelin-targeting chimeric antigen receptor-modified T cells by piggyBac transposon system suppress the growth of bile duct carcinoma. Tumour Biol. 2017;39:1010428317695949. [PMID: 28381173 DOI: 10.1177/1010428317695949] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 2.4] [Reference Citation Analysis]
157 Cavalloni G, Peraldo-Neia C, Sassi F, Chiorino G, Sarotto I, Aglietta M, Leone F. Establishment of a patient-derived intrahepatic cholangiocarcinoma xenograft model with KRAS mutation. BMC Cancer 2016;16:90. [PMID: 26868125 DOI: 10.1186/s12885-016-2136-1] [Cited by in Crossref: 25] [Cited by in F6Publishing: 22] [Article Influence: 4.2] [Reference Citation Analysis]
158 Altekruse SF, Petrick JL, Rolin AI, Cuccinelli JE, Zou Z, Tatalovich Z, McGlynn KA. Geographic variation of intrahepatic cholangiocarcinoma, extrahepatic cholangiocarcinoma, and hepatocellular carcinoma in the United States. PLoS One. 2015;10:e0120574. [PMID: 25837669 DOI: 10.1371/journal.pone.0120574] [Cited by in Crossref: 41] [Cited by in F6Publishing: 37] [Article Influence: 5.9] [Reference Citation Analysis]
159 Lee T, Lin J, Kuo KN, Wu M, Ho HJ, Chen T, Wu C. A nationwide population-based study shows increasing incidence of cholangiocarcinoma. Hepatol Int 2013;7:226-32. [DOI: 10.1007/s12072-012-9369-0] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.4] [Reference Citation Analysis]
160 Weiss MJ, Cosgrove D, Herman JM, Rastegar N, Kamel I, Pawlik TM. Multimodal treatment strategies for advanced hilar cholangiocarcinoma. Langenbecks Arch Surg. 2014;399:679-692. [PMID: 24962146 DOI: 10.1007/s00423-014-1219-1] [Cited by in Crossref: 21] [Cited by in F6Publishing: 14] [Article Influence: 2.6] [Reference Citation Analysis]
161 Petrick JL, Yang B, Altekruse SF, Van Dyke AL, Koshiol J, Graubard BI, McGlynn KA. Risk factors for intrahepatic and extrahepatic cholangiocarcinoma in the United States: A population-based study in SEER-Medicare. PLoS One. 2017;12:e0186643. [PMID: 29049401 DOI: 10.1371/journal.pone.0186643] [Cited by in Crossref: 57] [Cited by in F6Publishing: 52] [Article Influence: 11.4] [Reference Citation Analysis]
162 Choi J, Ghoz HM, Peeraphatdit T, Baichoo E, Addissie BD, Harmsen WS, Therneau TM, Olson JE, Chaiteerakij R, Roberts LR. Aspirin use and the risk of cholangiocarcinoma. Hepatology. 2016;64:785-796. [PMID: 26940227 DOI: 10.1002/hep.28529] [Cited by in Crossref: 49] [Cited by in F6Publishing: 48] [Article Influence: 8.2] [Reference Citation Analysis]
163 Nehls O, Oettle H, Hartmann JT, Hofheinz RD, Hass HG, Horger MS, Koppenhöfer U, Hochhaus A, Stieler J, Trojan J, Gregor M, Klump B. Capecitabine plus oxaliplatin as first-line treatment in patients with advanced biliary system adenocarcinoma: a prospective multicentre phase II trial. Br J Cancer 2008;98:309-15. [PMID: 18182984 DOI: 10.1038/sj.bjc.6604178] [Cited by in Crossref: 81] [Cited by in F6Publishing: 71] [Article Influence: 5.8] [Reference Citation Analysis]
164 She WH, Cheung TT, Ma KW, Yin Tsang SH, Dai WC, Yan Chan AC, Lo CM. Impact of preoperative biliary drainage on postoperative outcomes in hilar cholangiocarcinoma. Asian J Surg 2021:S1015-9584(21)00560-1. [PMID: 34588138 DOI: 10.1016/j.asjsur.2021.07.075] [Reference Citation Analysis]
165 Waseem D, Tushar P. Intrahepatic, perihilar and distal cholangiocarcinoma: Management and outcomes. Ann Hepatol. 2017;16:133-139. [PMID: 28051802 DOI: 10.5604/16652681.1226927] [Cited by in Crossref: 35] [Cited by in F6Publishing: 29] [Article Influence: 7.0] [Reference Citation Analysis]
166 Welzel TM, Graubard BI, El-Serag HB, Shaib YH, Hsing AW, Davila JA, McGlynn KA. Risk factors for intrahepatic and extrahepatic cholangiocarcinoma in the United States: a population-based case-control study. Clin Gastroenterol Hepatol. 2007;5:1221-1228. [PMID: 17689296 DOI: 10.1016/j.cgh.2007.05.020] [Cited by in Crossref: 314] [Cited by in F6Publishing: 284] [Article Influence: 20.9] [Reference Citation Analysis]
167 de Martel C, Plummer M, Franceschi S. Cholangiocarcinoma: descriptive epidemiology and risk factors. Gastroenterol Clin Biol. 2010;34:173-180. [PMID: 20202771 DOI: 10.1016/j.gcb.2010.01.008] [Cited by in Crossref: 28] [Cited by in F6Publishing: 23] [Article Influence: 2.3] [Reference Citation Analysis]
168 Koprowski S, Sokolowski K, Kunnimalaiyaan S, Gamblin TC, Kunnimalaiyaan M. Curcumin-mediated regulation of Notch1/hairy and enhancer of split-1/survivin: molecular targeting in cholangiocarcinoma. J Surg Res. 2015;198:434-440. [PMID: 25890434 DOI: 10.1016/j.jss.2015.03.029] [Cited by in Crossref: 18] [Cited by in F6Publishing: 19] [Article Influence: 2.6] [Reference Citation Analysis]
169 Ewald F, Nörz D, Grottke A, Hofmann BT, Nashan B, Jücker M. Dual Inhibition of PI3K-AKT-mTOR- and RAF-MEK-ERK-signaling is synergistic in cholangiocarcinoma and reverses acquired resistance to MEK-inhibitors. Invest New Drugs 2014;32:1144-54. [DOI: 10.1007/s10637-014-0149-7] [Cited by in Crossref: 28] [Cited by in F6Publishing: 28] [Article Influence: 3.5] [Reference Citation Analysis]
170 Yoon HA, Noh MH, Kim BG, Han JS, Jang JS, Choi SR, Jeong JS, Chun JH. Clinicopathological significance of altered Notch signaling in extrahepatic cholangiocarcinoma and gallbladder carcinoma. World J Gastroenterol 2011; 17(35): 4023-4030 [PMID: 22046092 DOI: 10.3748/wjg.v17.i35.4023] [Cited by in CrossRef: 30] [Cited by in F6Publishing: 28] [Article Influence: 2.7] [Reference Citation Analysis]
171 Kosaka H, Kaibori M, Matsui K, Ishizaki M, Matsushima H, Sekimoto M. Investigation of a Tumor Location-Specific Therapeutic Strategy for Intrahepatic Cholangiocarcinoma. Asian Pac J Cancer Prev 2021;22:1485-93. [PMID: 34048177 DOI: 10.31557/APJCP.2021.22.5.1485] [Reference Citation Analysis]
172 Konfortion J, Coupland VH, Kocher HM, Allum W, Grocock MJ, Jack RH. Time and deprivation trends in incidence of primary liver cancer subtypes in England. J Eval Clin Pract. 2014;20:498-504. [PMID: 24902884 DOI: 10.1111/jep.12188] [Cited by in Crossref: 11] [Cited by in F6Publishing: 13] [Article Influence: 1.4] [Reference Citation Analysis]
173 Möbius C, Demuth C, Aigner T, Wiedmann M, Wittekind C, Mössner J, Hauss J, Witzigmann H. Evaluation of VEGF A expression and microvascular density as prognostic factors in extrahepatic cholangiocarcinoma. Eur J Surg Oncol. 2007;33:1025-1029. [PMID: 17400419 DOI: 10.1016/j.ejso.2007.02.020] [Cited by in Crossref: 48] [Cited by in F6Publishing: 49] [Article Influence: 3.2] [Reference Citation Analysis]
174 Chung KD, Jeong YI, Chung CW, Kim DH, Kang DH. Anti-tumor activity of all-trans retinoic acid-incorporated glycol chitosan nanoparticles against HuCC-T1 human cholangiocarcinoma cells. Int J Pharm 2012;422:454-61. [PMID: 22093956 DOI: 10.1016/j.ijpharm.2011.10.057] [Cited by in Crossref: 16] [Cited by in F6Publishing: 15] [Article Influence: 1.5] [Reference Citation Analysis]
175 Brandi G, Tavolari S. Asbestos and Intrahepatic Cholangiocarcinoma. Cells 2020;9:E421. [PMID: 32059499 DOI: 10.3390/cells9020421] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
176 El Khatib M, Kalnytska A, Palagani V, Kossatz U, Manns MP, Malek NP, Wilkens L, Plentz RR. Inhibition of hedgehog signaling attenuates carcinogenesis in vitro and increases necrosis of cholangiocellular carcinoma. Hepatology 2013;57:1035-45. [DOI: 10.1002/hep.26147] [Cited by in Crossref: 58] [Cited by in F6Publishing: 100] [Article Influence: 6.4] [Reference Citation Analysis]
177 Flemming JA, Zhang-Salomons J, Nanji S, Booth CM. Increased incidence but improved median overall survival for biliary tract cancers diagnosed in Ontario from 1994 through 2012: A population-based study. Cancer 2016;122:2534-43. [PMID: 27183133 DOI: 10.1002/cncr.30074] [Cited by in Crossref: 15] [Cited by in F6Publishing: 14] [Article Influence: 2.5] [Reference Citation Analysis]
178 Shinohara ET, Guo M, Mitra N, Metz JM. Brachytherapy in the treatment of cholangiocarcinoma. Int J Radiat Oncol Biol Phys. 2010;78:722-728. [PMID: 20207503 DOI: 10.1016/j.ijrobp.2009.08.070] [Cited by in Crossref: 24] [Cited by in F6Publishing: 23] [Article Influence: 2.0] [Reference Citation Analysis]
179 Ishiguro S, Inoue M, Kurahashi N, Iwasaki M, Sasazuki S, Tsugane S. Risk factors of biliary tract cancer in a large-scale population-based cohort study in Japan (JPHC study); with special focus on cholelithiasis, body mass index, and their effect modification. Cancer Causes Control 2008;19:33-41. [PMID: 17906958 DOI: 10.1007/s10552-007-9067-8] [Cited by in Crossref: 41] [Cited by in F6Publishing: 38] [Article Influence: 2.7] [Reference Citation Analysis]
180 Kwak TW, Shin HJ, Jeong YI, Han ME, Oh SO, Kim HJ, Kim DH, Kang DH. Anticancer activity of streptochlorin, a novel antineoplastic agent, in cholangiocarcinoma. Drug Des Devel Ther 2015;9:2201-14. [PMID: 25931814 DOI: 10.2147/DDDT.S80205] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
181 Utada M, Ohno Y, Tamaki T, Sobue T, Endo G. Long-term trends in incidence and mortality of intrahepatic and extrahepatic bile duct cancer in Japan. J Epidemiol. 2014;24:193-199. [PMID: 24614916 DOI: 10.2188/jea.je20130122] [Cited by in Crossref: 21] [Cited by in F6Publishing: 6] [Article Influence: 2.6] [Reference Citation Analysis]
182 Müller L, Mähringer-Kunz A, Jungmann F, Tanyildizi Y, Bartsch F, Czauderna C, Düber C, Galle PR, Weinmann A, Kloeckner R, Hahn F. Risk Stratification in Advanced Biliary Tract Cancer: Validation of the A.L.A.N. Score. J Oncol 2020;2020:6180613. [PMID: 32684933 DOI: 10.1155/2020/6180613] [Reference Citation Analysis]
183 Van Dyke AL, Shiels MS, Jones GS, Pfeiffer RM, Petrick JL, Beebe-Dimmer JL, Koshiol J. Biliary tract cancer incidence and trends in the United States by demographic group, 1999-2013. Cancer 2019;125:1489-98. [PMID: 30645774 DOI: 10.1002/cncr.31942] [Cited by in Crossref: 37] [Cited by in F6Publishing: 40] [Article Influence: 12.3] [Reference Citation Analysis]
184 Fingas CD, Blechacz BR, Smoot RL, Guicciardi ME, Mott J, Bronk SF, Werneburg NW, Sirica AE, Gores GJ. A smac mimetic reduces TNF related apoptosis inducing ligand (TRAIL)-induced invasion and metastasis of cholangiocarcinoma cells. Hepatology 2010;52:550-61. [PMID: 20683954 DOI: 10.1002/hep.23729] [Cited by in Crossref: 46] [Cited by in F6Publishing: 42] [Article Influence: 3.8] [Reference Citation Analysis]
185 Singal AK, Vauthey JN, Grady JJ, Stroehlein JR. Intra-hepatic cholangiocarcinoma--frequency and demographic patterns: thirty-year data from the M.D. Anderson Cancer Center. J Cancer Res Clin Oncol. 2011;137:1071-1078. [PMID: 21207060 DOI: 10.1007/s00432-010-0971-z] [Cited by in Crossref: 41] [Cited by in F6Publishing: 37] [Article Influence: 3.7] [Reference Citation Analysis]
186 Floreani A, Lisiero M, Baldovin T, Baldo V. Epidemiological aspects of biliary tree tumors in a region of northern Italy: emerging trends and sex-based differences. Eur J Gastroenterol Hepatol 2013;25:1347-51. [PMID: 24081106 DOI: 10.1097/MEG.0b013e3283636cfb] [Cited by in Crossref: 6] [Cited by in F6Publishing: 2] [Article Influence: 0.8] [Reference Citation Analysis]
187 Jepsen P, Vilstrup H, Tarone RE, Friis S, Sorensen HT. Incidence Rates of Intra- and Extrahepatic Cholangiocarcinomas in Denmark From 1978 Through 2002. JNCI Journal of the National Cancer Institute 2007;99:895-7. [DOI: 10.1093/jnci/djk201] [Cited by in Crossref: 60] [Cited by in F6Publishing: 59] [Article Influence: 4.0] [Reference Citation Analysis]
188 Zhong F, Zhang S, Shao C, Yang J, Wu X. Arsenic trioxide inhibits cholangiocarcinoma cell growth and induces apoptosis. Pathol Oncol Res 2010;16:413-20. [PMID: 20012722 DOI: 10.1007/s12253-009-9234-1] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 0.4] [Reference Citation Analysis]
189 Miranda-Filho A, Piñeros M, Ferreccio C, Adsay V, Soerjomataram I, Bray F, Koshiol J. Gallbladder and extrahepatic bile duct cancers in the Americas: Incidence and mortality patterns and trends. Int J Cancer 2020;147:978-89. [PMID: 31922259 DOI: 10.1002/ijc.32863] [Cited by in Crossref: 7] [Cited by in F6Publishing: 9] [Article Influence: 3.5] [Reference Citation Analysis]
190 Khan SA, Emadossadaty S, Ladep NG, Thomas HC, Elliott P, Taylor-robinson SD, Toledano MB. Rising trends in cholangiocarcinoma: Is the ICD classification system misleading us? Journal of Hepatology 2012;56:848-54. [DOI: 10.1016/j.jhep.2011.11.015] [Cited by in Crossref: 168] [Cited by in F6Publishing: 156] [Article Influence: 16.8] [Reference Citation Analysis]
191 Lawal B, Kuo YC, Tang SL, Liu FC, Wu ATH, Lin HY, Huang HS. Transcriptomic-Based Identification of the Immuno-Oncogenic Signature of Cholangiocarcinoma for HLC-018 Multi-Target Therapy Exploration. Cells 2021;10:2873. [PMID: 34831096 DOI: 10.3390/cells10112873] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
192 Gatto M, Bragazzi MC, Semeraro R, Napoli C, Gentile R, Torrice A, Gaudio E, Alvaro D. Cholangiocarcinoma: Update and future perspectives. Digestive and Liver Disease 2010;42:253-60. [DOI: 10.1016/j.dld.2009.12.008] [Cited by in Crossref: 123] [Cited by in F6Publishing: 111] [Article Influence: 10.3] [Reference Citation Analysis]
193 Zhuang L, Meng Z, Yang Z. MRPL27 contributes to unfavorable overall survival and disease-free survival from cholangiocarcinoma patients. Int J Med Sci 2021;18:936-43. [PMID: 33456351 DOI: 10.7150/ijms.50782] [Reference Citation Analysis]
194 Brandi G, Di Girolamo S, Farioli A, de Rosa F, Curti S, Pinna AD, Ercolani G, Violante FS, Biasco G, Mattioli S. Asbestos: a hidden player behind the cholangiocarcinoma increase? Findings from a case-control analysis. Cancer Causes Control. 2013;24:911-918. [PMID: 23408245 DOI: 10.1007/s10552-013-0167-3] [Cited by in Crossref: 27] [Cited by in F6Publishing: 28] [Article Influence: 3.0] [Reference Citation Analysis]
195 Bertuccio P, Bosetti C, Levi F, Decarli A, Negri E, La Vecchia C. A comparison of trends in mortality from primary liver cancer and intrahepatic cholangiocarcinoma in Europe. Ann Oncol. 2013;24:1667-1674. [PMID: 23378539 DOI: 10.1093/annonc/mds652] [Cited by in Crossref: 74] [Cited by in F6Publishing: 76] [Article Influence: 8.2] [Reference Citation Analysis]
196 Kuang D, Wang G. Hilar cholangiocarcinoma: Pathology and tumor biology. Front Med China 2010;4:371-7. [DOI: 10.1007/s11684-010-0130-6] [Cited by in Crossref: 10] [Cited by in F6Publishing: 5] [Article Influence: 0.8] [Reference Citation Analysis]
197 Prueksapanich P, Piyachaturawat P, Aumpansub P, Ridtitid W, Chaiteerakij R, Rerknimitr R. Liver Fluke-Associated Biliary Tract Cancer. Gut Liver 2018;12:236-45. [PMID: 28783896 DOI: 10.5009/gnl17102] [Cited by in Crossref: 24] [Cited by in F6Publishing: 16] [Article Influence: 6.0] [Reference Citation Analysis]
198 Abbas G, Lindor KD. Cholangiocarcinoma in primary sclerosing cholangitis. J Gastrointest Cancer 2009;40:19-25. [PMID: 19705300 DOI: 10.1007/s12029-009-9085-8] [Cited by in Crossref: 14] [Cited by in F6Publishing: 11] [Article Influence: 1.1] [Reference Citation Analysis]
199 Poultsides GA, Zhu AX, Choti MA, Pawlik TM. Intrahepatic cholangiocarcinoma. Surg Clin North Am. 2010;90:817-837. [PMID: 20637950 DOI: 10.1016/j.suc.2010.04.011] [Cited by in Crossref: 78] [Cited by in F6Publishing: 69] [Article Influence: 6.5] [Reference Citation Analysis]
200 Myint KZ, Kongpracha P, Rattanasinganchan P, Leelawat K, Moolthiya P, Chaiyabutr K, Tohtong R. Gadd45β silencing impaired viability and metastatic phenotypes in cholangiocarcinoma cells by modulating the EMT pathway. Oncol Lett 2018;15:3031-41. [PMID: 29435034 DOI: 10.3892/ol.2017.7706] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 0.2] [Reference Citation Analysis]
201 El Khatib M, Bozko P, Palagani V, Malek NP, Wilkens L, Plentz RR. Activation of Notch signaling is required for cholangiocarcinoma progression and is enhanced by inactivation of p53 in vivo. PLoS One. 2013;8:e77433. [PMID: 24204826 DOI: 10.1371/journal.pone.0077433] [Cited by in Crossref: 38] [Cited by in F6Publishing: 36] [Article Influence: 4.2] [Reference Citation Analysis]
202 Bernuzzi F, Marabita F, Lleo A, Carbone M, Mirolo M, Marzioni M, Alpini G, Alvaro D, Boberg KM, Locati M. Serum microRNAs as novel biomarkers for primary sclerosing cholangitis and cholangiocarcinoma. Clin Exp Immunol. 2016;185:61-71. [PMID: 26864161 DOI: 10.1111/cei.12776] [Cited by in Crossref: 49] [Cited by in F6Publishing: 49] [Article Influence: 8.2] [Reference Citation Analysis]
203 Nathan H, Aloia TA, Vauthey JN, Abdalla EK, Zhu AX, Schulick RD, Choti MA, Pawlik TM. A proposed staging system for intrahepatic cholangiocarcinoma. Ann Surg Oncol. 2009;16:14-22. [PMID: 18987916 DOI: 10.1245/s10434-008-0180-z] [Cited by in Crossref: 219] [Cited by in F6Publishing: 189] [Article Influence: 15.6] [Reference Citation Analysis]
204 Arnold A, Bahra M, Lenze D, Bradtmöller M, Guse K, Gehlhaar C, Bläker H, Heppner FL, Koch A. Genome wide DNA copy number analysis in cholangiocarcinoma using high resolution molecular inversion probe single nucleotide polymorphism assay. Experimental and Molecular Pathology 2015;99:344-53. [DOI: 10.1016/j.yexmp.2015.08.003] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 1.1] [Reference Citation Analysis]
205 Hammill CW, Wong LL. Intrahepatic cholangiocarcinoma: a malignancy of increasing importance. J Am Coll Surg. 2008;207:594-603. [PMID: 18926465 DOI: 10.1016/j.jamcollsurg.2008.04.031] [Cited by in Crossref: 50] [Cited by in F6Publishing: 51] [Article Influence: 3.6] [Reference Citation Analysis]
206 Spolverato G, Ejaz A, Kim Y, Sotiropoulos GC, Pau A, Alexandrescu S, Marques H, Pulitano C, Barroso E, Clary BM, Aldrighetti L, Bauer TW, Walters DM, Groeschl R, Gamblin TC, Marsh W, Nguyen KT, Turley R, Popescu I, Hubert C, Meyer S, Gigot JF, Mentha G, Pawlik TM. Tumor size predicts vascular invasion and histologic grade among patients undergoing resection of intrahepatic cholangiocarcinoma. J Gastrointest Surg. 2014;18:1284-1291. [PMID: 24841438 DOI: 10.1007/s11605-014-2533-1] [Cited by in Crossref: 45] [Cited by in F6Publishing: 44] [Article Influence: 5.6] [Reference Citation Analysis]
207 She WH, Cheung TT, Ma KW, Tsang SHY, Dai WC, Chan ACY, Lo CM. Vascular resection and reconstruction in hilar cholangiocarcinoma. ANZ J Surg 2020;90:1653-9. [PMID: 32458528 DOI: 10.1111/ans.15969] [Cited by in Crossref: 3] [Article Influence: 1.5] [Reference Citation Analysis]
208 Chung YE, Kim MJ, Park YN, Choi JY, Pyo JY, Kim YC, Cho HJ, Kim KA, Choi SY. Varying appearances of cholangiocarcinoma: radiologic-pathologic correlation. Radiographics. 2009;29:683-700. [PMID: 19448110 DOI: 10.1148/rg.293085729] [Cited by in Crossref: 249] [Cited by in F6Publishing: 185] [Article Influence: 19.2] [Reference Citation Analysis]
209 Kovalenko YA, Zharikov YO. [Portal cholangiocarcinoma: epidemiology, staging principles and aspects of tumor biology]. Khirurgiia (Mosk) 2017;:85-91. [PMID: 29186104 DOI: 10.17116/hirurgia20171185-91] [Reference Citation Analysis]
210 Cao L, Xue P, Lu H, Zheng Q, Wen Z, Shao Z. Hematoporphyrin derivative-mediated photodynamic therapy inhibits tumor growth in human cholangiocarcinoma in vitro and in vivo. Hepatology Research 2009;39:1190-7. [DOI: 10.1111/j.1872-034x.2009.00569.x] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 0.6] [Reference Citation Analysis]
211 Lafaro KJ, Cosgrove D, Geschwind JF, Kamel I, Herman JM, Pawlik TM. Multidisciplinary Care of Patients with Intrahepatic Cholangiocarcinoma: Updates in Management. Gastroenterol Res Pract 2015;2015:860861. [PMID: 26089873 DOI: 10.1155/2015/860861] [Cited by in Crossref: 27] [Cited by in F6Publishing: 27] [Article Influence: 3.9] [Reference Citation Analysis]
212 Raoof M, Singh G. Rising trends in intrahepatic cholangiocarcinoma incidence and mortality: getting at the root cause. Hepatobiliary Surg Nutr 2019;8:301-3. [PMID: 31245420 DOI: 10.21037/hbsn.2019.01.15] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.7] [Reference Citation Analysis]
213 Cruz-Ramón V, Chinchilla-López P, Ramírez-Pérez O, Qi X, Méndez-Sánchez N. The Changing Face of the Diagnosis of Chronic and Malignant Liver Diseases: Potential New Biomarkers. Ann Hepatol 2018;17:14-7. [PMID: 29311406 DOI: 10.5604/01.3001.0010.7531] [Reference Citation Analysis]
214 Alvaro D, Cannizzaro R, Labianca R, Valvo F, Farinati F, Italian Society of Gastroenterology (SIGE), Italian Association of Hospital Gastroenterology (AIGO), Italian Association of Medical Oncology (AIOM), Italian Association of Oncological Radiotherapy (AIRO). Cholangiocarcinoma: A position paper by the Italian Society of Gastroenterology (SIGE), the Italian Association of Hospital Gastroenterology (AIGO), the Italian Association of Medical Oncology (AIOM) and the Italian Association of Oncological Radiotherapy (AIRO). Dig Liver Dis. 2010;42:831-838. [PMID: 20702152 DOI: 10.1016/j.dld.2010.06.005] [Cited by in Crossref: 23] [Cited by in F6Publishing: 17] [Article Influence: 1.9] [Reference Citation Analysis]
215 Bridgewater JA, Goodman KA, Kalyan A, Mulcahy MF. Biliary Tract Cancer: Epidemiology, Radiotherapy, and Molecular Profiling. American Society of Clinical Oncology Educational Book 2016. [DOI: 10.1200/edbk_160831] [Cited by in Crossref: 48] [Cited by in F6Publishing: 28] [Article Influence: 8.0] [Reference Citation Analysis]
216 Choi JY, Kim MJ, Lee JM, Kim KW, Lee JY, Han JK, Choi BI. Hilar cholangiocarcinoma: role of preoperative imaging with sonography, MDCT, MRI, and direct cholangiography. AJR Am J Roentgenol. 2008;191:1448-1457. [PMID: 18941084 DOI: 10.2214/ajr.07.3992] [Cited by in Crossref: 75] [Cited by in F6Publishing: 18] [Article Influence: 5.4] [Reference Citation Analysis]
217 Mukai Y, Matsuyama R, Koike I, Kumamoto T, Kaizu H, Homma Y, Takano S, Sawada Y, Sugiura M, Yabushita Y, Ito E, Sato M, Endo I, Hata M. Outcome of postoperative radiation therapy for cholangiocarcinoma and analysis of dose-volume histogram of remnant liver. Medicine (Baltimore) 2019;98:e16673. [PMID: 31374045 DOI: 10.1097/MD.0000000000016673] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
218 Asrani SK, Devarbhavi H, Eaton J, Kamath PS. Burden of liver diseases in the world. J Hepatol. 2019;70:151-171. [PMID: 30266282 DOI: 10.1016/j.jhep.2018.09.014] [Cited by in Crossref: 615] [Cited by in F6Publishing: 559] [Article Influence: 153.8] [Reference Citation Analysis]
219 He F, York JP, Burroughs SG, Qin L, Xia J, Chen D, Quigley EM, Webb P, LeSage GD, Xia X. Recruited metastasis suppressor NM23-H2 attenuates expression and activity of peroxisome proliferator-activated receptor δ (PPARδ) in human cholangiocarcinoma. Dig Liver Dis 2015;47:62-7. [PMID: 25277864 DOI: 10.1016/j.dld.2014.09.002] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 0.8] [Reference Citation Analysis]
220 Barat S, Bozko P, Chen X, Scholta T, Hanert F, Götze J, Malek NP, Wilkens L, Plentz RR. Targeting c-MET by LY2801653 for treatment of cholangiocarcinoma. Mol Carcinog 2016;55:2037-50. [PMID: 26757360 DOI: 10.1002/mc.22449] [Cited by in Crossref: 16] [Cited by in F6Publishing: 16] [Article Influence: 2.7] [Reference Citation Analysis]
221 Chen JH, Xiang JY, Ding GP, Cao LP. Cholangiocarcinoma-derived exosomes inhibit the antitumor activity of cytokine-induced killer cells by down-regulating the secretion of tumor necrosis factor-α and perforin. J Zhejiang Univ Sci B 2016;17:537-44. [PMID: 27381730 DOI: 10.1631/jzus.B1500266] [Cited by in Crossref: 17] [Cited by in F6Publishing: 9] [Article Influence: 3.4] [Reference Citation Analysis]
222 Matull WR, Khan SA, Pereira SP. Re: Impact of classification of hilar cholangiocarcinomas (Klatskin tumors) on incidence of intra- and extrahepatic cholangiocarcinoma in the United States. J Natl Cancer Inst. 2007;99:407; author reply 407-408. [PMID: 17341733 DOI: 10.1093/jnci/djk068] [Cited by in Crossref: 11] [Cited by in F6Publishing: 14] [Article Influence: 0.7] [Reference Citation Analysis]
223 Guettier C. [Case 5: Intrahepatic cholangiocarcinoma]. Ann Pathol 2007;27:104-11. [PMID: 17909466 DOI: 10.1016/s0242-6498(07)91293-6] [Reference Citation Analysis]
224 Sharma P, Yadav S. Demographics, tumor characteristics, treatment, and survival of patients with Klatskin tumors. Ann Gastroenterol 2018;31:231-6. [PMID: 29507471 DOI: 10.20524/aog.2018.0233] [Cited by in Crossref: 1] [Cited by in F6Publishing: 8] [Article Influence: 0.3] [Reference Citation Analysis]
225 Jackson MW, Amini A, Jones BL, Rusthoven CG, Schefter TE, Goodman KA. Treatment Selection and Survival Outcomes With and Without Radiation for Unresectable, Localized Intrahepatic Cholangiocarcinoma. Cancer J 2016;22:237-42. [PMID: 27441741 DOI: 10.1097/PPO.0000000000000213] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 2.4] [Reference Citation Analysis]